Argos Therapeutics Inc. (ARGS) Stock Price Up 6.1% Following Insider Buying Activity
Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) rose 6.1% during trading on Wednesday following insider buying activity. The stock traded as high as $5.07 and last traded at $5.07, with a volume of 117,289 shares trading hands. The stock had previously closed at $4.78.
Specifically, major shareholder International S. Pharmstandard bought 67,371 shares of Argos Therapeutics stock in a transaction on Wednesday, August 24th. The stock was purchased at an average cost of $4.52 per share, for a total transaction of $304,516.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder International S. Pharmstandard bought 16,977 shares of Argos Therapeutics stock in a transaction on Thursday, September 1st. The stock was acquired at an average price of $4.78 per share, with a total value of $81,150.06. The disclosure for this purchase can be found here. Corporate insiders own 61.64% of the company’s stock.
ARGS has been the subject of a number of analyst reports. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $11.00 target price on shares of Argos Therapeutics in a research note on Monday, June 20th. Zacks Investment Research cut shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. FBR & Co reiterated a “buy” rating on shares of Argos Therapeutics in a research note on Tuesday, June 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Argos Therapeutics in a research note on Friday, June 17th. Eight equities research analysts have rated the stock with a buy rating, Argos Therapeutics currently has an average rating of “Buy” and an average target price of $11.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/argos-therapeutics-inc-args-stock-price-up-6-1-following-insider-buying-activity.html
The stock has a 50-day moving average price of $4.80 and a 200 day moving average price of $5.96. The company’s market cap is $210.10 million.
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.05. On average, equities research analysts expect that Argos Therapeutics Inc. will post ($1.55) EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 3,559 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in shares of Argos Therapeutics during the second quarter valued at $137,000. California State Teachers Retirement System acquired a new position in shares of Argos Therapeutics during the second quarter valued at $137,000. KCG Holdings Inc. acquired a new position in shares of Argos Therapeutics during the second quarter valued at $163,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 33,862 shares in the last quarter. 11.05% of the stock is owned by institutional investors.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.